Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALB | P02768 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | TK1 | P04183 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30976665 | 0.85 | LMNA (0.59) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14596611 | 0.80 | LMNA (0.53) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL933552 | 0.79 | LMNA (0.54) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL11959652 | 0.78 | ALDH1A1 (0.51) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL10438691 | 0.78 | ALDH1A1 (0.50) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL464791 | 0.78 | LMNA (0.56) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL1417635 | 0.77 | LMNA (0.62) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL2158702 | 0.77 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14232397 | 0.77 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL18837842 | 0.76 | TK1 (0.66) | LMNAALBBLMTK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2932970-A1 | ANTIVIRAL THERAPY | VIIV Healthcare Company (US) | 2015-10-21 | — | — | EP | claimed |
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | LIAONING LIFENG SCIENT & TECHNOLOGY DEV COMPANY LTD (CN) | 2015-06-04 | — | — | US | claimed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | claimed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | claimed |
| EP-1686113-B1 | Inhibitors of aspartyl protease | VERTEX PHARMA (US) | 2011-11-23 | — | — | EP | claimed |
| JP-4503896-B2 | — | — | 2010-07-14 | — | — | JP | claimed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | claimed |
| WO-2009075960-A1 | CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | claimed |
| WO-2009058924-A1 | CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | claimed |
| WO-2009058919-A1 | CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | claimed |
| EP-1363877-A2 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | claimed |
| US-6599887-B2 | Aids, herpes virus | CHIMERIX, INC. | 2003-07-29 | — | — | US | claimed |
| JP-2003502309-A | — | — | 2003-01-21 | — | — | JP | claimed |
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | GALENICA PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | claimed |
| WO-2002070470-A2 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | claimed |
| US-6448392-B1 | LIPID, ESPECIALLY PHOSPHOLIPID, DERIVATIVES OF MODIFIED ANTIVIRAL NUCLEOSIDE ANALOGUES CAN BE INTEGRATED INTO STRUCTURE OF LIPOSOMES, FORMING STABLE LIPOSOMAL COMPLEX, DELIVER GREATER AMOUNTS OF DRUGS TO CELLS WITH LESS TOXICITY | CHIMERIX, INC. | 2002-09-10 | — | — | US | claimed |
| EP-1194404-A1 | INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2002-04-10 | — | — | EP | claimed |
| US-20010033862-A1 | Methods of treating viral infections using antiviral liponucleotides | HOSTETLER KARL Y (US) | 2001-10-25 | — | — | US | claimed |
| WO-2000076961-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-12-21 | — | — | WO | claimed |
| EP-0350287-A2 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | NeXstar Pharmaceuticals, Inc. (US) | 1990-01-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | CYP11B1, CYP51A1, CYP11B2 | LMNA 2583/4885ALB 4628/4885BLM 2884/4885 |
| US-20010033862-A1 | Methods of treating viral infections using antiviral liponucleotides | PHOSPHO1, TK1, TYMP | LMNA 2418/4885ALB 3062/4885BLM 3761/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | LMNA 4130/4885ALB 3777/4885BLM 4822/4885 |
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | TLR1, ICOS, TLR2 | LMNA 4648/4885ALB 1470/4885BLM 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.